Richard Adler, MD, FACS, Assistant Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins Institute, and Director of Ophthalmology Services at Belcara Health, discusses the critical unmet needs in Dry Eye Disease (DED) therapies and explores the potential impact of new agents in addressing these challenges.
Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).
Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED.
Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies.
Richard Adler, MD, FACS, provides insights on data presented at AA0 2023, from a study comparing results of the ARMOR procedure versus treatment with cyclosporine ophthalmic emulsion 0.05% in patients with dry eye disease.
Richard Adler, MD, FACS, provides perspective on AAO 2023 data suggesting dual mechanism treatment targeting aqueous deficiency and meibomian gland dysfunction may improve dry eye symptoms more significantly and faster than singular therapies, benefiting patient compliance and disease management.
